1730 related articles for article (PubMed ID: 27012484)
1. Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria.
Dubois B; Hampel H; Feldman HH; Scheltens P; Aisen P; Andrieu S; Bakardjian H; Benali H; Bertram L; Blennow K; Broich K; Cavedo E; Crutch S; Dartigues JF; Duyckaerts C; Epelbaum S; Frisoni GB; Gauthier S; Genthon R; Gouw AA; Habert MO; Holtzman DM; Kivipelto M; Lista S; Molinuevo JL; O'Bryant SE; Rabinovici GD; Rowe C; Salloway S; Schneider LS; Sperling R; Teichmann M; Carrillo MC; Cummings J; Jack CR;
Alzheimers Dement; 2016 Mar; 12(3):292-323. PubMed ID: 27012484
[TBL] [Abstract][Full Text] [Related]
2. Application of the IWG-2 Diagnostic Criteria for Alzheimer's Disease to the ADNI.
Wang HF; Tan L; Cao L; Zhu XC; Jiang T; Tan MS; Liu Y; Wang C; Tsai RM; Jia JP; Yu JT;
J Alzheimers Dis; 2016; 51(1):227-36. PubMed ID: 26836176
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in cerebrospinal fluid biomarkers for the detection of preclinical Alzheimer's disease.
Kulic L; Unschuld PG
Curr Opin Neurol; 2016 Dec; 29(6):749-755. PubMed ID: 27805971
[TBL] [Abstract][Full Text] [Related]
4. Dissociation of amyloid biomarkers in PET and CSF in Alzheimer's disease: a case report.
Schroeter ML; Tiepolt S; Marschhauser A; Thöne-Otto A; Hoffmann KT; Barthel H; Obrig H; Sabri O
BMC Neurol; 2015 Aug; 15():152. PubMed ID: 26303364
[TBL] [Abstract][Full Text] [Related]
5. [The new 2011 recommendations of the National Institute on Aging and the Alzheimer's Association on diagnostic guidelines for Alzheimer's disease: Preclinal stages, mild cognitive impairment, and dementia].
Croisile B; Auriacombe S; Etcharry-Bouyx F; Vercelletto M; ;
Rev Neurol (Paris); 2012 Jun; 168(6-7):471-82. PubMed ID: 22579080
[TBL] [Abstract][Full Text] [Related]
6. Preclinical cerebrospinal fluid and volumetric magnetic resonance imaging biomarkers in Swedish familial Alzheimer's disease.
Thordardottir S; Ståhlbom AK; Ferreira D; Almkvist O; Westman E; Zetterberg H; Eriksdotter M; Blennow K; Graff C
J Alzheimers Dis; 2015; 43(4):1393-402. PubMed ID: 25182737
[TBL] [Abstract][Full Text] [Related]
7. Neuroimaging biomarkers for Alzheimer's disease in asymptomatic APOE4 carriers.
Chételat G; Fouquet M
Rev Neurol (Paris); 2013 Oct; 169(10):729-36. PubMed ID: 24016463
[TBL] [Abstract][Full Text] [Related]
8. Biomarkers for preclinical Alzheimer's disease.
Tan CC; Yu JT; Tan L
J Alzheimers Dis; 2014; 42(4):1051-69. PubMed ID: 25024325
[TBL] [Abstract][Full Text] [Related]
9. In vivo detection of microstructural correlates of brain pathology in preclinical and early Alzheimer Disease with magnetic resonance imaging.
Zhao Y; Raichle ME; Wen J; Benzinger TL; Fagan AM; Hassenstab J; Vlassenko AG; Luo J; Cairns NJ; Christensen JJ; Morris JC; Yablonskiy DA
Neuroimage; 2017 Mar; 148():296-304. PubMed ID: 27989773
[TBL] [Abstract][Full Text] [Related]
10. On the path to 2025: understanding the Alzheimer's disease continuum.
Aisen PS; Cummings J; Jack CR; Morris JC; Sperling R; Frölich L; Jones RW; Dowsett SA; Matthews BR; Raskin J; Scheltens P; Dubois B
Alzheimers Res Ther; 2017 Aug; 9(1):60. PubMed ID: 28793924
[TBL] [Abstract][Full Text] [Related]
11. PRECISION MEDICINE - The Golden Gate for Detection, Treatment and Prevention of Alzheimer's Disease.
Hampel H; O'Bryant SE; Castrillo JI; Ritchie C; Rojkova K; Broich K; Benda N; Nisticò R; Frank RA; Dubois B; Escott-Price V; Lista S
J Prev Alzheimers Dis; 2016 Dec; 3(4):243-259. PubMed ID: 28344933
[TBL] [Abstract][Full Text] [Related]
12. Critical Comparison of Different Biomarkers for Alzheimer's Disease in a Clinical Setting.
Weise D; Tiepolt S; Awissus C; Hoffmann KT; Lobsien D; Kaiser T; Barthel H; Sabri O; Gertz HJ
J Alzheimers Dis; 2015; 48(2):425-32. PubMed ID: 26402006
[TBL] [Abstract][Full Text] [Related]
13. Rethinking on the concept of biomarkers in preclinical Alzheimer's disease.
Berti V; Polito C; Lombardi G; Ferrari C; Sorbi S; Pupi A
Neurol Sci; 2016 May; 37(5):663-72. PubMed ID: 26792010
[TBL] [Abstract][Full Text] [Related]
14. Early diagnosis and treatment of Alzheimer's disease: new definitions and challenges.
Pais M; Martinez L; Ribeiro O; Loureiro J; Fernandez R; Valiengo L; Canineu P; Stella F; Talib L; Radanovic M; Forlenza OV
Braz J Psychiatry; 2020 Aug; 42(4):431-441. PubMed ID: 31994640
[TBL] [Abstract][Full Text] [Related]
15. Current opinion neurology: visual pathway biomarkers in Alzheimer's disease.
Van Stavern GP
Curr Opin Neurol; 2020 Feb; 33(1):79-86. PubMed ID: 31809334
[TBL] [Abstract][Full Text] [Related]
16. When Does Alzheimer's Disease Really Start? The Role of Biomarkers.
Lloret A; Esteve D; Lloret MA; Cervera-Ferri A; Lopez B; Nepomuceno M; Monllor P
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31698826
[TBL] [Abstract][Full Text] [Related]
17. FDG-PET and amyloid-PET imaging: the diverging paths.
Perani D
Curr Opin Neurol; 2014 Aug; 27(4):405-13. PubMed ID: 24927239
[TBL] [Abstract][Full Text] [Related]
18. NIA-AA staging of preclinical Alzheimer disease: discordance and concordance of CSF and imaging biomarkers.
Vos SJB; Gordon BA; Su Y; Visser PJ; Holtzman DM; Morris JC; Fagan AM; Benzinger TLS
Neurobiol Aging; 2016 Aug; 44():1-8. PubMed ID: 27318129
[TBL] [Abstract][Full Text] [Related]
19. Subtle Cognitive Decline and Biomarker Staging in Preclinical Alzheimer's Disease.
Edmonds EC; Delano-Wood L; Galasko DR; Salmon DP; Bondi MW;
J Alzheimers Dis; 2015; 47(1):231-42. PubMed ID: 26402771
[TBL] [Abstract][Full Text] [Related]
20. Patterns of Cortical and Subcortical Amyloid Burden across Stages of Preclinical Alzheimer's Disease.
Edmonds EC; Bangen KJ; Delano-Wood L; Nation DA; Furst AJ; Salmon DP; Bondi MW;
J Int Neuropsychol Soc; 2016 Nov; 22(10):978-990. PubMed ID: 27903335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
